Cannabidiol Effects on Fear Extinction in Social Phobia

Status Not yet recruiting

Clinical Trial Summary

The investigators will randomly assign participants with social anxiety disorder to receive oral cannabidiol (CBD) or placebo. Participants will undergo a fear conditioning and extinction trial, and the investigators will examine whether CBD increases the degree of fear reduction during extinction.

Clinical Trial Description

This will be a double-blind, randomized controlled trial of cannabidiol (CBD) vs. placebo for potentiating fear extinction in adult outpatients with social anxiety disorder (SAD). After providing written informed consent and passing medical screening, participants will be assessed for SAD and other mental health concerns. They will then engage in a fear conditioning paradigm in which an electrical stimulation is applied to the wrist that is aversive but not painful (at a level determined by each participant) paired with pictures of angry faces. Following the fear conditioning paradigm, they will receive orally administered CBD or placebo. They will then undergo a fear extinction phase in which the conditioned angry faces are shown repeatedly with no further electrical stimulus. Fear toward the conditioned faces following extinction will be measured using galvanic skin response (GSR) and a visual analog scale of self-reported fear. The investigators predict that CBD, compared to placebo, will result in lower GSR and self-reported fear ratings. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06123702
Study type	Interventional
Source	Hartford Hospital
Contact	David Tolin, Ph.D.
Phone	860-545-7685
Email	david.tolin@hhchealth.org
Status	Not yet recruiting
Phase	Early Phase 1
Start date	April 30, 2024
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06274112` - Using TMS to Understand Neural Processes of Social Motivation	N/A
Completed	`NCT02554929` - Treatment of Social Anxiety Disorder and Selective Mutism	N/A
Completed	`NCT00684541` - Interpretation Modification Program for Social Phobia	N/A
Completed	`NCT00684320` - Attention Disengagement Training for Social Phobia	N/A
Completed	`NCT03247075` - Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT	N/A
Completed	`NCT02811458` - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders	N/A
Withdrawn	`NCT04622930` - Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)	N/A
Active, not recruiting	`NCT05018312` - Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety	N/A
Completed	`NCT05858294` - The Safety, Acceptability and Efficacy of Alena	N/A
Active, not recruiting	`NCT05600114` - Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder	Phase 2
Not yet recruiting	`NCT06081348` - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders	Phase 2
Not yet recruiting	`NCT02924610` - Brief Intervention to Reduce Fear	Phase 4
Active, not recruiting	`NCT02592564` - Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder	N/A
Recruiting	`NCT02305537` - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment	N/A
Terminated	`NCT03764644` - Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders	N/A
Unknown status	`NCT01712321` - Study of Vilazodone to Treat Social Anxiety Disorder	N/A
Completed	`NCT01320800` - CBT for Social Anxiety Disorder Delivered by School Counselors	Phase 2
Completed	`NCT00773162` - Flushing in Social Anxiety Disorder on Seroquel	Phase 3
Completed	`NCT00485615` - An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia	Phase 2
Completed	`NCT00872820` - Examining Long-Term Effects and Neural Mediators of Behavioral Treatments for Social Anxiety Disorder	N/A